SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 22.77 Billion KRW | -105.32% |
| 2022 | 142.25 Billion KRW | -66.89% |
| 2021 | 492.99 Billion KRW | 719.51% |
| 2020 | 57.97 Billion KRW | 70.14% |
| 2019 | 37.21 Billion KRW | 65.82% |
| 2018 | 21.1 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -26.17 Billion KRW | -1656.54% |
| 2024 Q2 | -18.99 Billion KRW | 27.14% |
| 2024 Q3 | -39.61 Billion KRW | -422.04% |
| 2023 Q2 | -20.46 Billion KRW | -2412.51% |
| 2023 Q1 | 885.12 Million KRW | -90.54% |
| 2023 Q3 | 105.48 Billion KRW | 615.34% |
| 2023 Q4 | -1.97 Billion KRW | -101.87% |
| 2023 FY | - KRW | -105.32% |
| 2022 FY | - KRW | -66.89% |
| 2022 Q4 | 9.35 Billion KRW | -80.37% |
| 2022 Q3 | 47.63 Billion KRW | -41.41% |
| 2022 Q2 | 81.3 Billion KRW | 142.84% |
| 2022 Q1 | 33.48 Billion KRW | -87.21% |
| 2021 Q1 | 57.77 Billion KRW | 187.38% |
| 2021 FY | - KRW | 719.51% |
| 2021 Q4 | 261.84 Billion KRW | 148.11% |
| 2021 Q3 | 105.53 Billion KRW | 45.59% |
| 2021 Q2 | 72.48 Billion KRW | 25.47% |
| 2020 FY | - KRW | 70.14% |
| 2020 Q2 | 1.01 Billion KRW | 125.42% |
| 2020 Q3 | 44.29 Billion KRW | 4258.2% |
| 2020 Q4 | 20.1 Billion KRW | -54.62% |
| 2020 Q1 | -3.99 Billion KRW | -139.15% |
| 2019 FY | - KRW | 65.82% |
| 2019 Q4 | 10.21 Billion KRW | -2.36% |
| 2019 Q3 | 10.45 Billion KRW | -48.51% |
| 2019 Q2 | 20.31 Billion KRW | 501.07% |
| 2019 Q1 | -5.06 Billion KRW | -184.79% |
| 2018 Q4 | 5.97 Billion KRW | -51.49% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q3 | 12.31 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | -45.381% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | 65.924% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 79.258% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -169.858% |
| Green Cross Corporation | 109.81 Billion KRW | 79.258% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 135.757% |
| Celltrion, Inc. | 897.26 Billion KRW | 97.462% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 98.58% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 202.577% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 173.361% |